Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Goldberg, MD
Oncorus, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- City of Hope
Duarte, California, United States
- Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory University
Atlanta, Georgia, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- the Ohio State University Wexner Medical Center James Cancer Hospital
Columbus, Ohio, United States
- Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, United States
- the University of Texas at Austin
Austin, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 May 2020
- Primary completion
- 31 May 2023
- Completion
- 31 May 2023
- Last update posted
- 8 Jun 2023
- Registered enrollment
- 66
- Registry id
- NCT04348916
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.